The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications
Top Cited Papers
- 4 February 2012
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 24 (2), 225-232
- https://doi.org/10.1016/j.coi.2012.01.010
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- CD47–signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destructionProceedings of the National Academy of Sciences, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic LeukemiaCancer Research, 2011
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin LymphomaCell, 2010
- Macrophages as mediators of tumor immunosurveillanceTrends in Immunology, 2010
- Radioprotection in Normal Tissue and Delayed Tumor Growth by Blockade of CD47 SignalingScience Translational Medicine, 2009
- Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cellsProceedings of the National Academy of Sciences, 2009
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cellsThe Journal of cell biology, 2008